Genomics of ECT

Overview

About this study

The purpose of this study is to determine if genetic analysis of participants treated with ECT will identify gene loci associated with severe mood disorders, including major depressive disorder (MDD) or bipolar disorder (BPD), at genome-wide significance in comparison to participants with milder mood disorders.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subject is over age 18 at time of consent, has a primary lifetime diagnosis of MDD or BPD.
  • Is currently receiving ECT.
  • Has received ECT in the past.
  • iI/was a candidate for ECT but declined or opted for another non-first line treatment, such as repetitive transcranial magnetic stimulation or IV/IN ketamine.
  • Is/was admitted and treated in the hospital for a severe major depressive episode.

Exclusion Criteria::

  • Subject has a history of significant head trauma with loss of consciousness.
  • Subject has a lifetime diagnosis of a primary psychotic disorder (e.g., schizophrenia or schizoaffective disorder).
  • Subject is not able to provide consent due to cognitive or other impairments as deemed by the treating physician.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/17/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mark Frye, M.D.

Open for enrollment

Contact information:

Mark Frye M.D.

(507) 255-9412

MFrye@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20568204

Mayo Clinic Footer